At the same time, as LMIC governments increasingly shoulder more of the costs of treating NCDs, including T1DM, for their population, they must create an enabling environment for a range of insulin products and improve procurement processes and price negotiations, with a goal of driving down prices while improving access to evidence-supported, cost-effective treatments. Here, INS is linked to type 1 diabetes mellitus.